About The Study: In this analysis of the top 1,000 generics in Colorado’s all-payer claims database in 2019, researchers identified 45 high-cost products that had lower-cost therapeutic alternatives of same clinical value. Overall, high-cost generics were 15.6 times more expensive than their therapeutic alternatives (median values). If the lower-cost alternatives had been used, total spending would have been reduced by 88%. Substitution of high-cost generics may provide a simple pathway to offer the same therapeutic benefit at lower cost to patients and insurers.
Authors: Mariana P. Socal, M.D., Ph.D., of the Johns Hopkins Bloomberg School of Public Health in Baltimore, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2022.39868)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2022.39868?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=110222
Journal
JAMA Network Open